Combining Ketoconazole and Bazedoxifene to Fight Breast Cancer
Author Information
Author(s): Manore Sara, Zhuang Chuling, Najjar Mariana K., Wong Grace L., Bindal Shivani, Watabe Kounosuke, Lin Jiayuh, Lo Hui-Wen, Weiskirchen Ralf
Primary Institution: Wake Forest University School of Medicine
Hypothesis
Co-targeting tGLI1 and IL-6R/GP130 signaling pathways will be synergistic against HER2-enriched and triple-negative breast cancers.
Conclusion
The combination of Ketoconazole and Bazedoxifene effectively reduces tumor growth and metastasis in aggressive breast cancer subtypes.
Supporting Evidence
- tGLI1 and GP130 are co-overexpressed in 53.8% and 44.4% of HER2-enriched and TNBC cases, respectively.
- Combination therapy significantly reduced cell viability and suppressed breast cancer stem cell phenotypes.
- KCZ and BZA treatment led to decreased tumor growth and metastatic burden in mouse models.
Takeaway
Researchers found that using two existing drugs together can help fight certain types of breast cancer better than using them alone.
Methodology
The study involved in vitro and in vivo experiments using breast cancer cell lines and patient-derived xenograft models to assess the effects of the drug combination on cancer cell viability and metastasis.
Limitations
The study primarily focuses on in vitro and animal models, which may not fully replicate human responses.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website